Educational content on VJHemOnc is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Share this video  

EHA 2019 | Glasdegib therapy for MDS and AML

David Sallman • 15 Jun 2019
EHA 2019
Acute Myeloid Leukemia Myelodysplastic Syndromes Glasdegib

David Sallman, MD, Moffitt Cancer Center, Tampa, FL, discusses the use of glasdegib therapy for relapsed/refractory myelodysplastic syndromes and oligoblastic acute myeloid leukemia at the 24th Congress of the European Hematology Association (EHA) 2019, held in Amsterdam, Netherlands.

More from David Sallman

2:08
Hematological response to frontline treatment in LR-MDS is associated with better OS
David Sallman • 9 Dec 2023
1:58
Canakinumab plus darbepoetin in patients with LR-MDS following ESA failure
David Sallman • 9 Dec 2023
2:49
Front-line treatment options for HR-MDS: can we move past azacitidine?
David Sallman • 9 Dec 2023
Transplantation & immunotherapies
Charles Craddock et al. • 4 Sep 2023

Related Videos

1:40
The role of CPX-351 in the AML treatment landscape & insights into the AMLSG 30-18 trial
Felicitas Thol • 19 Apr 2024
3:21
Integrating genomics and MRD in transplant decision-making for patients with AML
Jurjen Versluis • 22 Apr 2024
2:22
Haplo-SCT for older patients with AML/MDS, and should age be a barrier to transplantation?
Raynier Devillier • 15 Apr 2024
2:31
Emerging treatment options for patients with ESA-refractory MDS: luspatercept & imetelstat
Eva Hellström-Lindberg • 11 Apr 2024
The content of VJHemOnc is intended for healthcare professionals